Nautilus Biotechnology (NAUT) Scheduled to Post Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect Nautilus Biotechnology to post earnings of ($0.17) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. During the same period in the prior year, the firm earned ($0.13) EPS. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nautilus Biotechnology Price Performance

NAUT stock opened at $2.77 on Tuesday. Nautilus Biotechnology has a 1 year low of $2.19 and a 1 year high of $3.45. The company has a market cap of $346.98 million, a P/E ratio of -5.04 and a beta of 1.22. The stock’s fifty day moving average price is $2.70 and its 200-day moving average price is $2.61.

Analysts Set New Price Targets

Separately, Guggenheim began coverage on Nautilus Biotechnology in a research note on Thursday, June 27th. They set a “buy” rating and a $6.00 price target for the company.

Insiders Place Their Bets

In other news, VP Mary E. Godwin sold 47,031 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.